Recent News

• 11.05.2026 - Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
• 11.05.2026 - Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
• 11.05.2026 - Lantheus Reports Third Quarter 2026 Financial Results
• 11.05.2026 - Lantheus Reports Third Quarter 2026 Financial Results
• 11.02.2026 - Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
• 11.02.2026 - Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
• 09.30.2026 - Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
• 09.30.2026 - Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
• 09.30.2026 - Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
• 09.28.2026 - Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Recent Filings

• 11.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 10.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.22.2026 - 8-K Current report
• 10.14.2026 - 8-K Current report
• 10.02.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 10.02.2026 - 8-K Current report
• 09.23.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership